Ondansetron (Latran) 4 mg – [10 tablets]

Description

Latran Pharmacodynamics
It has antiemetic and anxiolytic activity.
Ondansetron is a selective 5HTH3 receptor (serotonin) antagonist. Cytostatic chemotherapy drugs and radiotherapy may cause an increase in serotonin concentrations, which by activating afferent fibers of the vagus nerve containing 5NT3 receptors, causes the gag reflex. It selectively blocks serotonin 5HT3-receptors of central (gag center) and peripheral (gastrointestinal tract) nervous system neurons that regulate the gag reflex. Does not impair coordination of movements, does not cause sedation and decreased performance. It does not change the plasma concentration of prolactin.

Indications
Prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy and radiation therapy in adults; prevention and treatment of nausea and vomiting caused by other types of radiation exposure in adults; prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy in children; prevention of postoperative nausea and vomiting in adults.

Contraindications
– Hypersensitivity to the active substance or to any other component of the drug;
– concomitant use of ondansetron with apomorphine;
– pregnancy and breast-feeding;
– children under 3 years of age for the prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy;
– Children under 18 years of age for prevention and treatment of nausea and vomiting caused by radiation therapy, and for prevention of postoperative nausea and vomiting;
– congenital QT interval prolongation syndrome.
If you have one of the above mentioned conditions, consult your physician before taking the drug.
Caution
– Patients with hypersensitivity to other 5HT3-receptor antagonists, with cardiac rhythm and conduction disorders;
– in patients receiving antiarrhythmic drugs and beta-adrenoblockers;
– in patients with significant abnormalities of water-electrolyte balance;
– patients with prolongation or risk of QTc interval prolongation, including patients with electrolyte-water balance disorders, chronic heart failure, bradyarrhythmia, or patients taking other medications that may cause QTc interval prolongation or electrolyte-water balance disorders or reduced heart rate;
– in patients with subacute intestinal obstruction;
– concomitant use with other serotonergic drugs.
Administration during pregnancy and breast feeding
Latran® is contraindicated for use during pregnancy and breast feeding.

How to use and dosages.

• By mouth.
• Prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy and radiotherapy in adults
• The choice of dosage regimen is determined by the emetogenicity of antitumor therapy and may vary with the dose and combinations of chemotherapy and radiotherapy regimens used.
• Adults
• The recommended dose is 8 mg ondansetron 1-2 hours before the start of cytostatic chemotherapy or radiotherapy followed by oral administration of 8 mg every 12 hours for not more than
  5 days.
• In high-emetogenic chemotherapy, a single oral dose of ondansetron is 24 mg simultaneously with oral dexamethasone in a dose of 12 mg 1-2 hours before the start of chemotherapy.
• Within the first 24 hours after chemotherapy or radiation therapy, it is possible to continue the use of the drug Latran® orally for not more than 5 days. It is recommended to take Latran® orally in a dose of 8 mg twice a day.